Prime Med­i­cine CSO de­parts, re­veals new fund­ing; FDA lifts par­tial hold on Kezar drug

Plus, news about OKYO Phar­ma, Mo­di Ven­tures and Bri­a­Cell Ther­a­peu­tics:

More changes at Prime Med­i­cine: The biotech said Chief Sci­en­tif­ic Of­fi­cer Je­re­my Duffield is leav­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER